Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)
Ocular Therapeutix (OCUL) posted quarterly Convertible Debt of $9.1 million for Q4 2023, down 68.21% year-over-year from $28.7 million in Q4 2022, and up 4.26% on a QoQ basis from $8.8 million in Q3 2023.
Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023) Analysis & Trends
Ocular Therapeutix has reported Convertible Debt for 5 years, with the latest figure at $9.1 million in Q4 2023.
- Convertible Debt for Q4 2023 came in at $9.1 million, down 68.21% year-over-year; the trailing twelve-month figure through Dec 2023 was $9.1 million (down 68.21% YoY), and the FY2023 annual result was $9.1 million, down 68.21% from the prior year.
- Convertible Debt rose to $9.1 million in Q4 2023, from $8.8 million in the prior quarter.
- Over five years, Convertible Debt peaked at $30.0 million in Q2 2023 and troughed at $8.8 million in Q3 2023.
- A 5-year average of $24.3 million and a median of $25.3 million in 2020 frame the typical range for Convertible Debt.
- The widest annual swing landed in 2020, when Convertible Debt increased 10.27%; it then slumped 68.87% in 2023.
- A 5-year view of Convertible Debt shows it stood at $24.3 million in 2019, then advanced by 0.01% to $24.3 million in 2020, then rose by 8.75% to $26.4 million in 2021, then gained by 8.75% to $28.7 million in 2022, then sank by 68.21% to $9.1 million in 2023.
- Per Business Quant data, the three most recent Convertible Debt figures were $9.1 million in Q4 2023, $8.8 million in Q3 2023, and $30.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 9.14 Mn |
| Sep 30, 2023 | 8.77 Mn |
| Jun 30, 2023 | 29.98 Mn |
| Mar 31, 2023 | 29.36 Mn |
| Dec 31, 2022 | 28.75 Mn |
| Sep 30, 2022 | 28.15 Mn |
| Jun 30, 2022 | 27.57 Mn |
| Mar 31, 2022 | 27.00 Mn |
| Dec 31, 2021 | 26.44 Mn |
| Sep 30, 2021 | 25.89 Mn |
| Jun 30, 2021 | 25.35 Mn |
| Mar 31, 2021 | 24.82 Mn |
| Dec 31, 2020 | 24.31 Mn |
| Sep 30, 2020 | 23.80 Mn |
| Jun 30, 2020 | 26.35 Mn |
| Mar 31, 2020 | 25.30 Mn |
| Dec 31, 2019 | 24.31 Mn |
| Sep 30, 2019 | 23.15 Mn |
| Jun 30, 2019 | 23.90 Mn |
| Mar 31, 2019 | 23.01 Mn |